These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12213397)

  • 1. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
    Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
    da Silva VO; Borja-Cabrera GP; Correia Pontes NN; de Souza EP; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2000 Dec; 19(9-10):1082-92. PubMed ID: 11137242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
    Santos WR; de Lima VM; de Souza EP; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Nov; 21(1-2):30-43. PubMed ID: 12443660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
    Paraguai de Souza E; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2001 Apr; 19(23-24):3104-15. PubMed ID: 11312005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.
    Mohammadi-Ghalehbin B; Hatam G; Sarkari B; Mohebali M; Zarei Z; Bohlooli S
    Iran J Immunol; 2017 Dec; 14(4):293-305. PubMed ID: 29276182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
    Palatnik de Sousa CB; Gomes EM; de Souza EP; dos Santos WR; de Macedo SR; de Medeiros LV; Luz K
    Rev Soc Bras Med Trop; 1996; 29(2):153-63. PubMed ID: 8713607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
    Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
    Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
    Santos WR; Bernardo RR; Peçanha LM; Palatnik M; Parente JP; Palatnik de Sousa CB
    Vaccine; 1997 Jun; 15(9):1024-9. PubMed ID: 9261952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
    Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Parra LE; Borja-Cabrera GP; Santos FN; Souza LO; Palatnik-de-Sousa CB; Menz I
    Vaccine; 2007 Mar; 25(12):2180-6. PubMed ID: 17239495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
    Santos WR; Aguiar IA; Paraguai de Souza E; de Lima VM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2003 Dec; 21(32):4668-76. PubMed ID: 14585674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.
    Palatnik de Sousa CB; Santos WR; Casas CP; Paraguai de Souza E; Tinoco LW; da Silva BP; Palatnik M; Parente JP
    Vaccine; 2004 Jun; 22(19):2470-9. PubMed ID: 15193411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.